Hope Rugo, Professor of Medicine and Director of the Breast Oncology Clinical Trials Program at the University of California at San Francisco, shared a post by ESMO Open on X, adding:
“So excited to see this data published! Congrats to Saya Jacob, Geoff Shapiro and our amazing collaborators at DFCI and TBCRC!”
Quoting ESMO Open‘s post:
“TBCRC 035: randomized ph II pharmacodynamic study of standard and reduced-dose palbociclib with ET in HR+ previously treated metastatic BC in ESMO Open.
Lower dose of palbociclib may reduce severe neutropenia without compromising molecular response.”
Title: TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer
Authors: S. Jacob, E.L. Mayer, N. Kacik, A.M. Storniolo, C. Isaacs, I. Mayer, V. Stearns, R. Nanda, J. Nangia, A.J. Chien, M. Moasser, M. Melisko, C. Wabl, A. Muzikansky, J. Geradts, D.A. Dillon, B.H. Park, I. Krop, A.C. Wolff, B. Kochupurakkal, G.I. Shapiro, H.S. Rugo
Read The Full Article
Other articles about Breast Cancer on OncoDaily.